Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation


Phase N/A Results

Trial Description

The key focus of this survey will be to collect data on physicians awareness of the content of the Pradaxa® Prescriber Guide and the extent to which risk awareness is communicated to patients. The data collected with atrial fibrillation patients will show if and how well this information is received and understood.

Detailed Description



Trial Design

  • Observation: Cohort
  • Perspective: Cross-Sectional
  • Sampling: Probability Sample

Trial Population

Physicians prescribing dabigatran for patients with atrial fibrillation


Type Measure Time Frame Safety Issue
Primary Physician`s knowledge and recommendations to their patients on appropriate dosing and minimizing the risk of bleeding when treated with Pradaxa® (questionnaire) day 1 Yes
Primary Patient`s understanding of the disease, bleeding signs, what to do in case of bleeding and how to deal with emergency situations (measuring physician compliance from patient perspective) (questionnaire) day 1 Yes
Primary Physician's Knowledge and Recommendations to Their Patients on Appropriate Dosing and Minimizing the Risk of Bleeding When Treated With Pradaxa® (Questionnaire) Day 1 No
Primary Patient's Understanding of the Disease, Bleeding Signs, What to do in Case of Bleeding and How to Deal With Emergency Situations (Measuring Physician Compliance From Patient Perspective) (Questionnaire) Day 1 No